Details of the Drug

General Information of Drug (ID: DMTZ8RQ)

Drug Name
N-hydroxy-3-phenoxybenzamide
Synonyms CHEMBL245741; N-hydroxy-3-phenoxybenzamide; SCHEMBL6671653
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 229.23
Topological Polar Surface Area (xlogp) 3.2
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
Chemical Identifiers
Formula
C13H11NO3
IUPAC Name
N-hydroxy-3-phenoxybenzamide
Canonical SMILES
C1=CC=C(C=C1)OC2=CC=CC(=C2)C(=O)NO
InChI
InChI=1S/C13H11NO3/c15-13(14-16)10-5-4-8-12(9-10)17-11-6-2-1-3-7-11/h1-9,16H,(H,14,15)
InChIKey
WFZFBIHVPMBSOS-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
10192705
TTD ID
D0P3SU

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase 8 (HDAC8) TTT6LFV HDAC8_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2874-8.
2 Clinical pipeline report, company report or official report of NatureWise Biotech & Medicals.
3 HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.